Who are Rotavirus Vaccine (ROTARIX)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Stamaril, Sanofi Pasteur, Measles, Mumps, Rubella vaccination, Bacillus Calmette-Guerin (BCG), Bacille Calmette Guerin (BCG), MMR vaccination, Measles vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rotavirus-vaccine-rotarix.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Rotavirus Vaccine (ROTARIX) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rotavirus Vaccine (ROTARIX) (Rotavirus Vaccine (ROTARIX)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated vaccine. Area: Immunology / Infectious Disease.

marketed Live attenuated vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Rotavirus Vaccine (ROTARIX) (Rotavirus Vaccine (ROTARIX)) — International Centre for Diarrhoeal Disease Research, Bangladesh. ROTARIX is a live attenuated rotavirus vaccine that stimulates the immune system to produce antibodies and cellular immunity against rotavirus infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Rotavirus Vaccine (ROTARIX) TARGET	Rotavirus Vaccine (ROTARIX)	International Centre for Diarrhoeal Disease Research, Bangladesh	marketed	Live attenuated vaccine
Stamaril, Sanofi Pasteur	Stamaril, Sanofi Pasteur	Epicentre	marketed	Live attenuated vaccine	Yellow fever virus (17D strain)
Measles, Mumps, Rubella vaccination	Measles, Mumps, Rubella vaccination	N.M. Wulffraat	marketed	Live attenuated vaccine
Bacillus Calmette-Guerin (BCG)	Bacillus Calmette-Guerin (BCG)	Massachusetts General Hospital	marketed	Live attenuated vaccine / Immunotherapy
Bacille Calmette Guerin (BCG)	Bacille Calmette Guerin (BCG)	Bandim Health Project	marketed	Live attenuated vaccine
MMR vaccination	MMR vaccination	Klara M. Pósfay Barbe	marketed	Live attenuated vaccine
Measles vaccine	Measles vaccine	Bandim Health Project	marketed	Live attenuated vaccine	Measles virus surface glycoproteins (H and F proteins)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated vaccine class)

GlaxoSmithKline · 19 drugs in this class
Merck Sharp & Dohme LLC · 11 drugs in this class
Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
PATH · 5 drugs in this class
Sanofi · 5 drugs in this class
Bandim Health Project · 5 drugs in this class
Centers for Disease Control and Prevention · 3 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
Beijing Center for Disease Control and Prevention · 2 drugs in this class
Aga Khan University · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rotavirus Vaccine (ROTARIX) — Competitive Intelligence Brief. https://druglandscape.com/ci/rotavirus-vaccine-rotarix. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab